Breakthrough study reveals the cause of Alzheimer’s and Dementia

A new study has uncovered a surprising player in the decline of brain health linked to Alzheimer’s disease and vascular dementia. Researchers found that microglial cells—the brain’s cleanup crew—are being destroyed by a process called ferroptosis, a form of cell death driven by iron buildup. This finding could reshape the path forward for treating neurodegenerative conditions.

The research, published in Annals of Neurology, points to ferroptosis as the reason microglia die off in dementia. These immune cells are essential for brain health. They patrol the brain, respond to injury, and remove damaged or excess material. But in doing their job, they may be digging their own grave.

When the protective coating around nerve fibers, known as myelin, breaks down, it releases large amounts of iron. Microglia step in to clean up the mess, absorbing the iron-rich debris. The new study shows this overload of iron sparks ferroptosis, leading to the death of the very cells meant to protect the brain.

“Microglia play a vital role in preserving brain function,” said senior author Stephen Back, M.D., Ph.D. “But the same function that supports the brain may ultimately lead to their loss.” As microglia vanish, the brain loses its frontline defense against further injury and degeneration.

To uncover these findings, the team at Oregon Health & Science University examined human brain tissue from patients with Alzheimer’s and vascular dementia. They zeroed in on regions where microglia were most active and vulnerable. The link between iron, myelin damage, and ferroptosis became clear under the microscope.

This breakthrough offers a fresh path for scientists exploring new treatments. Blocking ferroptosis could protect microglia, preserving their ability to maintain brain health. It’s a promising direction for slowing or preventing the damage seen in dementia.

“This is a major finding,” emphasized Dr. Back, who has an extensive research background in myelin studies, especially concerning developmental delays in premature infants. The current findings, he says, takes this research further by revealing the interplay between neurodegeneration and myelin deterioration.

The innovative technique that made this discovery possible was spearheaded by the study’s lead author, Philip Adeniyi, Ph.D., a postdoctoral researcher in Dr. Back’s laboratory. This cutting-edge method brought into sharp focus the role of microglia in the white matter regions of Alzheimer's and vascular dementia patients' brains.

Dr. Back, reflecting on the significance of these findings, remarked, “We’ve missed a major form of cell death in Alzheimer’s disease and vascular dementia. It’s just amazing that we missed this until now.”

It's a revelation that's set to transform the way we perceive Alzheimer’s and vascular dementia. Co-author Kiera Degener-O’Brien, M.D., was the first to notice microglial degeneration in tissue samples. Building on this, Adeniyi's immunofluorescence technique confirmed that it was iron toxicity from myelin fragments leading to this degeneration. In essence, these immune cells were succumbing while performing their protective functions.

Dr. Back highlighted the previously underestimated role of microglia, saying, “Everyone knows that microglia are activated to mediate inflammation. But no one knew that they were dying in such large numbers.”

These findings have broad implications. The progressive decline of microglia may very well be a driving mechanism behind the cognitive deterioration seen in Alzheimer’s and vascular dementia patients. Recognizing this, Dr. Back anticipates a surge of interest from the pharmaceutical industry.

“That’s where the field will go next,” he asserted, hopeful about the development of compounds targeting microglial degeneration.

The starting point of this degenerative cycle likely roots back to repeated episodes of reduced blood flow and diminished oxygen supply to the brain. Factors such as acute stroke or chronic conditions, including hypertension and diabetes, might be contributing culprits.

Dr. Back concluded with a profound thought, “Dementia is a process that goes on for years and years. We have to tackle this from the early days to have an impact so that it doesn’t spin out of control.”

As we stand on the cusp of this breakthrough, the field of dementia research has received a renewed impetus. This discovery, encapsulating the pivotal role of ferroptosis, presents an untapped reservoir of opportunities for scientists, researchers, and pharmaceutical pioneers.

Only time will tell how this newfound knowledge shapes the future of dementia care and therapeutics.

Note: Materials provided above by The Brighter Side of News. Content may be edited for style and length.

Like these kind of feel good stories? Get The Brighter Side of News' newsletter.